

Oxular Appoints Robert Waters as Vice-President of Regulatory Affairs

- Robert Waters joins from Astellas where he was Global Regulatory Lead and previously Allergan where he was Head of Regulatory Development Europe
- 15 years of ophthalmic development and regulatory expertise

14 December 2016 – Oxular Limited, formally Precision Ocular Limited, the Oxford-based retinal therapeutics company, today announces that it has appointed Robert Waters to the position of Vice-President of Regulatory Affairs. Robert will be accountable for the Company's Regulatory Affairs function including strategic leadership and operational execution of all regulatory activities related to the development and registration of Oxular's product pipeline.

Robert brings over 15 years of extensive expertise in the development and registration of drug products and devices in ophthalmology. He joins Oxular from Astellas in Leiden where he has been working as a Global Regulatory Lead on urology and ophthalmology projects. Previously he worked at Allergan for nearly 10 years in various key European regulatory roles including Head of Ophthalmology and Head of Regulatory Development. At Allergan Robert led a number of teams responsible for obtaining drug product approvals in glaucoma and back of eye diseases including the European registration of OZURDEX™ for RVO, Uveitis and DME. Robert also spent 5 years at Bausch & Lomb where he gained early experience developing ophthalmic drug device combinations for the US & Europe.

Robert is a registered Pharmacist and holds a PhD in Analytical Chemistry from The School of Pharmacy, University of London.

Tom Cavanagh, Chief Executive Officer of Oxular Ltd, commented:

"We are delighted to welcome Robert to the Oxular team. Robert's deep knowledge in global regulation combined with his extensive experience in progressing ophthalmology projects to approval will be a great asset to the Company as we look to bring new ophthalmic products to market. As a young company, we are proud to attract somebody of Robert's calibre within the ophthalmology field and we believe that he will play a key role in helping us to achieve our goal of building a global ophthalmic franchise based on the successful development and commercialisation of our innovative and much needed treatments for retinal diseases."

Enquiries:

FTI Consulting

Ben Atwell / Mo Noonan

Tel: +44 (0)20 3727 1000

About Oxular Limited

Founded in 2014, Oxular is developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The unique approach aims to increase therapeutic effectiveness, reduce side-effects and minimise frequency of treatments. Oxular's product development pipeline includes treatments for both prevalent retinal diseases, such as age related macular degeneration and diabetic macular oedema, as well as rare and orphan indications (www.oxular.com).